(Domiphen bromide + miconazole) is under clinical development by Female Healthcare Purna and currently in Phase II for Vulvovaginal Candidiasis. According to GlobalData, Phase II drugs for Vulvovaginal Candidiasis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Domiphen bromide + miconazole)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Domiphen bromide + miconazole) overview

Miconazole is in combination with domiphen bromide is under development for the treatment of severe and recurrent vulvovaginal candidiasis (rVVC). It is administered through vaginal route as cream. Miconazole acts by targeting lanosterol 14 alpha demethylase. 

Female Healthcare Purna overview

Female Healthcare Purna is engaged to develop and commercialize therapy for the treatment of recurrent vulvovaginal candidiasis. The company is a spin off of Purna Pharmaceuticals NV. The company is headquartered in East Flanders, Belgium.

For a complete picture of (Domiphen bromide + miconazole)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.